最新发布
Practical lessons for public-private partnerships in agrifood
Public-private partnerships are essential to redirect the $842 billion spent on agriculture globally each year toward cu…
How African Agritech Founders Turned Farming Problems Into Businesses
38 KEY POINTS A large share of African agritech founders grew up on farms or watched their parents farm, and that childh…
Bezos Earth Fund joins Yield Lab Institute’s Global Cattle Innovation program as ‘catalytic funder’
The Yield Lab Institute (YLI) this week announced the Bezos Earth Fund as “catalytic funder” of its Global C…
Guest article: A landscape-scale strategy for regenerative agriculture
Stephen Wood is a senior scientist for agriculture & food systems at The Nature Conservancy, where he carries out sc…
SRTD raises €31.5M seed round to develop cell-selective RNA therapies
The funding round is led by Mérieux Equity Partners. Alongside NRW.BANK (contributing €7 million to the round), the Boehringer Ingelheim Venture Fund is also joining as a co-lead investor. Other participants include Lilly Ventures, High-Tech Gründerfonds (HTGF) and Freiburg-based family office Anobis. The capital will be used to advance the preclinical development of the company’s drug pipeline in cancer, autoimmune diseases and fibrosis, preparing the programs for clinical trials.
Swiss VC Redalpine closes eighth fund at $250 million
Its predecessor, Redalpine Capital VII, closed at $200 million in 2024. The new fund is therefore 25% larger. This development contrasts with the overall decline in fundraising in German-speaking countries. According to PitchBook data, 83 venture capital funds closed in 2022, raising a combined €6.2 billion. In the first nine months of 2025, only 21 funds closed, raising a total of €2 billion. The median time between a fund’s launch and final closing most recently stood at 26 months.
Boehringer-Zealand obesity drug clears cardiovascular safety hurdle, but tolerability concerns remain
Why it matters: According to Zealand Pharma, the November 9 SYNCHRONIZE-CVOT results complete the registrational Phase 3 program intended to support Boehringer’s planned regulatory submissions for obesity. Boehringer describes it as “the first and only global cardiovascular safety trial of a glucagon/GLP-1 dual agonist to date.”
Oyster Therapeutics raises $60M to bring Alzheimer’s tau degrader to clinic
Why it matters: Approved disease-modifying treatments for Alzheimer’s, including Leqembi and Kisunla, target amyloid plaques in the brain. Oyster is pursuing another hallmark of the disease: abnormal accumulations of tau inside neurons, which are associated with neuronal damage and cognitive decline.
Novo, Novartis drugs cut heart-risk markers but not cardiovascular events
Why it matters: Both trials tested ways to prevent heart attacks and strokes beyond lowering LDL cholesterol, one by suppressing inflammation and the other by reducing lipoprotein(a) (Lp(a)) a largely inherited cardiovascular risk factor elevated in approximately one in five people. Their failures challenge two closely watched drug-development strategies but do not establish conclusively that either biological target is ineffective.
Windward targets $204M IPO; Valneva’s Shigella vaccine meets Phase 2 endpoint; Ethris’ nasal mRNA lowers viral load
Windward targets $204 million from IPO and Sanofi placement: The Swiss biotech plans to offer approximately 10.3 million shares at $16–$18 each. At the midpoint, the offering and a separate $50 million Sanofi investment would generate approximately $203.8 million in combined net proceeds. Founded in 2024 and publicly launched in January 2025 with a $200 million Series A, Windward is pursuing Nasdaq less than two years after launch, following its $165 million Series B. Its model combines experienced leadership — CEO Luca Santarelli previously built Therachon and VectivBio — with clinical-stage medicines licensed from China. The proceeds would support respiratory and dermatology studies of WIN378, an anti-TSLP antibody, and WIN027, which targets TSLP and IL-13. The IPO remains pending.